Quantcast
Last updated on April 16, 2014 at 16:55 EDT

Latest Crohn's disease Stories

2012-10-22 22:44:23

Provide new insights on Infliximab use, disease characteristics, fistulizing Crohn's disease Three separate studies presented today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas help to advance understanding of the differences between African American and Caucasian patients with Inflammatory Bowel Disease (IBD) and provide clinicians with new insight on how racial disparities involving disease characteristics, infliximab use, and...

2012-10-22 07:30:36

SAN DIEGO, Oct. 22, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, will present five abstracts at the American College of Gastroenterology 2012 Scientific Meeting taking place this week in Las Vegas, NV. These data add to the compelling body of evidence that supports standardized use of liquid phase assays in helping to identify potential causes for loss of treatment response among inflammatory bowel disease (IBD) patients using...

2012-10-18 11:25:43

ATLANTA, Oct. 18, 2012 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology and neuroscience treatment and research, is marking the 2012 American College of Gastroenterology (ACG) Annual Scientific meeting in Las Vegas, Nevada by reinforcing its commitment to improving the lives of patients with Crohn's disease. UCB will present scientific data at this year's ACG meeting, October 19-24. "The annual ACG meeting gives UCB the opportunity to demonstrate our ongoing...

2012-10-17 15:22:50

SPRING HOUSE, Pa., Oct. 17, 2012 /PRNewswire/ -- Findings from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial evaluating the efficacy and safety of STELARA(®) (ustekinumab) in the treatment of moderate to severe Crohn's disease appeared today in The New England Journal of Medicine. The results showed that among patients who had previously failed or were intolerant to at least one tumor necrosis factor (TNF) antagonist, a significantly greater proportion...

2012-10-15 11:27:59

MOUNTAIN VIEW, Calif., Oct. 15, 2012 /PRNewswire/ -- In a new theoretical study, 23andMe, the leading personal genetics company, developed a mathematical model which shows that family history and genetic tests offer different strengths. The study results suggest that both family history and genetics are best used in combination to improve disease risk prediction. The full results of the study have now been published online in the journal PLOS Genetics. Family history is most useful in...

2012-09-24 22:29:20

Michigan State University researchers have unlocked secrets in bone marrow that could lead to improved treatments for colitis and Crohn´s disease. The results, featured in the current issue of Proceedings of the National Academy of the Sciences, show that the havoc inflammatory bowel diseases wreaks on the digestive tract is mirrored in bone marrow. Early indications also show that the disorders of the gut could potentially be treated through the bone marrow, said Pam Fraker, MSU...

2012-09-24 10:25:30

OAK BROOK, Ill., Sept. 24, 2012 /PRNewswire-USNewswire/ -- Each year more than 140,000 people in the United States are diagnosed with colon cancer and approximately 50,000 will die from the disease. All men and women are at risk for colon cancer. However, because of disproportionate screening rates, minorities, including Hispanics, are more likely to be diagnosed with colon cancer in advanced stages. Survival rates after diagnosis are also lower for Hispanics and this may be due to less...

2012-09-13 02:27:20

PRINCETON, N.J., Sept. 13, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the company), a development stage biopharmaceutical company announced today that the US Patent Office granted patent 8,263,582 entitled "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of beclomethasone dipropionate (BDP) in orally administered dosage forms that act...

2012-09-06 02:31:26

PRINCETON, N.J., Sept. 6, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction treatment of pediatric Crohn's disease. Soligenix has previously received Orphan Drug Designation for oral BDP...

Drug Gets Green Light To Treat Ulcerative Colitis
2012-08-29 16:29:05

Lee Rannals for redOrbit.com — Your Universe Online People suffering from ulcerative colitis may be getting some new relief due to a decision by the Food and Drug Administration (FDA) to expand the use of a new drug to help alleviate symptoms. An FDA panel voted 15 to 2 that the benefits of Humira outweighed the risks it causes when treating the condition. Humira is already approved to be used for six other conditions, and is most popular for its use to help in rheumatoid...